Lighting the Way to a Cure

  • Financials
  • Patient Library
  • Blog
  • Calendar
en English
en Englishes Spanishfr Frenchde Germanit Italiannl Dutchru Russianzh-CN Chinese (Simplified)ja Japanesehi Hindiiw Hebrewpt Portuguese
FSHD Header Logo
mobile-logo
  • Who We Are
        • About Us
          • History
          • Mission
          • Our Team
        • Our Impact
          • Therapeutic Accelerator
          • Education
          • Advocacy
          • Our Partners
        • Extraordinary Measures
          • 2021 Donor Impact Report
          • 2020 Donor Impact Report
  • Understanding FSHD
        • What is FSHD
          • Symptoms
          • Diagnosis
          • Early-onset FSHD
          • Genetic Testing
        • Living with FSHD
          • Newly Diagnosed?
          • Finding Care
          • Symptom Management
          • Patient Library
        • FSHD University
          • Physical Health
          • Wellness
          • Research
  • Get Involved
        • Support Us
          • Ways to Give
          • Become a Torchbearer
          • Raise Awareness
          • Volunteer
          • Fundraise
        • Advance Research
          • Patient Involvement
          • True Cost of FSHD Study
          • Clinical Trials
          • Donate tissue
        • Connect
          • Find Your Local Chapter
          • Join the Community
          • World FSHD Alliance
          • Online Communities
        • Events
          • Walk & Roll to Cure FSHD
          • Events Calendar
          • FSHD 360 Regional Conferences
          • FSHD Connect Conference
  • Research
        • For Patients & Families
          • Advance Research
          • True Cost of FSHD Study
          • TestFSHD genetic testing
          • Clinical Trials
        • For Researchers
          • Apply for a Grant
          • Research We Have Funded
          • Resources
          • Int’l Research Congress
        • For Clinicians
          • FSHD Masterclass
          • ICD-10
        • For Industry
          • Therapeutic Accelerator
          • Clinical Trial Research Network
          • Drug Development Pipeline
          • Voice of the Patient Report
  • News
    • Media Library
    • Blog
      • Living with FSHD
        • Health and Medicine
        • PT and Exercise
        • Tips and Tricks
        • Mental Health
      • FSHD Society News
      • FSHD Research
      • Fundraising & Events
      • Media & PR
    • FSHD Society Radio
    • The FSHD Advocate
  • JOIN US
  • DONATE

Drug Development Pipeline

Home / Therapeutic Accelerator / Drug Development Pipeline

Growing numbers of companies and academic laboratories are pressing forward with early-stage drug development efforts.

This chart shows how far various candidate anti-DUX4 drugs have progressed along the path to FDA approval. DUX4 is considered a key gene causing FSHD Types 1 and 2.

Drug Development Pipeline
Patients Accelerating Clinical Trials or PACT
Get email alerts. Join our Research Contact Registry. Click Here

*Repurposed drugs - compounds that were developed for other diseases and tested in the clinic. Some of them may have been approved for treatment of a specific disease, while others may have been shown to be safe but failed to be effective in these other indications and thus were abandoned. When a repurposed drug is found to work in the Target ID stage, it can often rapidly advance to the clinic, saving years and millions of dollars in preclinical testing.

 

**Anonymous biotechs & pharmas - many companies operate in stealth mode for business reasons. The FSHD Society maintains relationships with these companies, providing assistance to get their FSHD programs off the ground. When they go public, we will update you, so stay informed by signing up for email alerts and following us on social media.

The drug development process begins with finding a “target,” or biological disease mechanism, that can be modified by a therapy. Candidate compounds are identified based on their ability to “engage the target” and alter the disease mechanism (typically done in a test tube). Compounds that have the best properties to succeed as a drug are selected to be a “lead” (this is “lead optimization”). Lead compounds then go through a series of “preclinical” experiments, such as testing in an animal model. If a compound looks promising, a company may file an investigational new drug (IND) application with the FDA seeking permission to begin clinical trials in humans. The drug must then go through several trial phases before the company can file a new drug application (NDA), seeking permission from the FDA to put the drug on the market.

Small molecule drugs are chemical compounds that consist of up to about 100 atoms and are made through chemical synthesis. Being small, they can be more easily administered, for example, as a pill and pass through the digestive tract into the bloodstream to reach and penetrate cells. Biologics are very large molecules (such as RNA and proteins) derived from living organisms. They tend to be more precise and targeted, and therefore more effective. Because of their large size, they are usually delivered by injection or infusion, and getting them inside cells can be challenging.

Note, there are other proposed interventions, including nutritional supplements, nonpharmacologic interventions, growth hormone, etc., but they are not currently included in this diagram. Our colleagues at the FSHD UK patient registry maintain a broader list of therapies in development, including those in very early stages.

Sign up for Email Alerts

Stay up to date with the latest FSHD news and updates from FSHD Society.

CONNECT WITH US

Proud Member World FSHD Alliance (1)
Footer-Logo-min

Donation Address:

Department 960, P O Box 4106
Woburn, MA 01888    U.S.A.

General Mailing Address:

75 North Main Street, Suite 1073
Randolph, MA 02368 U.S.A.

(781) 301-6060

  • DONATE
  • Donate
  • Join Us
  • Inclusivity & Equity
  • Privacy Policy
  • Contact Us
  • Glossary Of Scientific Terms
Digital Marketing by